stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) Total debt
GSK PLC Sponsored ADR's total debt at the end of fiscal 2025 was $23.4B, up 7.65% from $21.7B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $31.9B. Over the past ten years it has ranged from $21.7B (fiscal 2024) to $39.0B (fiscal 2019); the current reading is higher than 36% of that period. GSK PLC Sponsored ADR ranks 9th of 21 Drug Manufacturers General companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $23.4B | 7.65% |
| FY2024 | $21.7B | (3.15%) |
| FY2023 | $22.4B | (13.66%) |
| FY2022 | $26.0B | (21.91%) |
| FY2021 | $33.2B | (4.65%) |
| FY2020 | $34.9B | (10.51%) |
| FY2019 | $39.0B | 11.97% |
| FY2018 | $34.8B | 57.96% |
| FY2017 | $22.0B | (13.52%) |
| FY2016 | $25.5B | 0.14% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $31.9B | 30.23% |
| Jun 2026 | $24.5B | (4.68%) |
| Mar 2026 | $25.7B | 9.89% |
| Dec 2025 | $23.4B | (2.33%) |
| 43 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PFE Pfizer Inc. compare | $62.7B |
| AMGN Amgen Inc. compare | $54.0B |
| BMY Bristol Myers Squibb Company compare | $42.9B |
| GSK GSK PLC Sponsored ADR | $31.9B |
| AZN AstraZeneca PLC compare | $31.4B |
| GILD Gilead Sciences, Inc. compare | $26.2B |
| NVO Novo Nordisk A/S compare | $21.8B |
| SNY Sanofi compare | $20.7B |
| BIIB Biogen Inc. compare | $7.3B |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement